The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endometrial cancer (EMC). Patients and Methods: Eligible patients had persistent or recurrent EMC after receiving one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of ≤ 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression or prohibitive toxicity. VEGF-A was assessed by immunohistochemistry in archival tumor and by enzyme-linked immunosorbent assay in pretreatment plasma. Primary end points were progression-free survival (PFS) at 6 months and overall response rate. Results: Fifty-six patients were enrolled. Fifty-two patients were eligible and evaluable. Median age was 62 years, and prior treatment consisted of one or two regimens in 33 (63.5%) and 19 (36.5%) patients, respectively. Twenty-nine patients (55.8%) received prior radiation. Adverse events were consistent with those expected with bevacizumab treatment. No GI perforations or fistulae were seen. Seven patients (13.5%) experienced clinical responses (one complete response and six partial responses; median response duration, 6.0 months), and 21 patients (40.4%) survived progression free for at least 6 months. Median PFS and overall survival times were 4.2 and 10.5 months, respectively. Suggested associations were observed between high VEGF-A and adjusted hazard of death or tumor response when evaluated in tumor/plasma or plasma, respectively. Conclusion: Bevacizumab is well tolerated and active based on PFS at 6 months in recurrent or persistent EMC and warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Self-citationAltered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Fleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565
Molecular and Pathologic Aspects of Endometrial Carcinogenesis
Hecht, J. L., & Mutter, G. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7173 · Cited by 535
Thigpen, J. T., Brady, M. F., Alvarez, R. D., Adelson, M. D., Homesley, H. D., Manetta, A., Soper, J. T., & Given, F. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1736 · Cited by 484
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Self-citationFleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P. A., Horowitz, I. R., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300
Self-citationSlomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269
Kurose, K., Zhou, X.-P., Araki, T., Cannistra, S. A., Maher, E. R., & Eng, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64681-0 · Cited by 252
Fiorica, J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.008 · Cited by 249
Whitney, C. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.09.018 · Cited by 193
Thigpen, T., Brady, M. F., Homesley, H. D., Soper, J. T., & Bell, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.364 · Cited by 191
Lentz, S. S., Brady, M. F., Major, F. J., Reid, G. C., & Soper, J. T. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.357 · Cited by 187
Lincoln, S., Blessing, J. A., Lee, R. B., & Rocereto, T. F. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00068-9 · Cited by 175
Muggia, F. M., Blessing, J. A., Sorosky, J., & Reid, G. C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.171 · Cited by 166
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148
Oza, A. M., Eisenhauer, E. A., Elit, L. M., Cutz, J.-C., Sakurada, A., Tsao, M., Hoskins, P. J., Biagi, J. J., Ghatage, P., Mazurka, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8808 · Cited by 152
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
Colombo, N., McMeekin, S., Schwartz, P. E., Kostka, J., Sessa, C., Gehrig, P. A., Holloway, R., Braly, P. S., Matei, D. E., & Einstein, M. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5516 · Cited by 100
Miller, D. S., Blessing, J. A., Lentz, S. S., & Waggoner, S. E. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6804 · Cited by 92
McMeekin, D. S., Sill, M. W., Benbrook, D. M., Darcy, K. M., Stearns-Kurosawa, D. J., Eaton, L. A., & Yamada, S. D. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.019 · Cited by 89
Self-citationOza, A. M., Elit, L., Biagi, J. J., Chapman, W., Tsao, M., Hedley, D. W., Hansen, C. P., Dancey, J. E., & Eisenhauer, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3003 · Cited by 89
PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells.
Zhu, X., Kwon, C. H., Schlosshauer, P. W., Ellenson, L. H., & Baker, S. J. (2001) · PubMed · Cited by 81
Oza, A. M., Elit, L., Provencher, D. M., Biagi, J. J., Panasci, L., Sederias, J., Dancey, J. E., Tsao, M., & Eisenhauer, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5516 · Cited by 53
Rose, P. G., Blessing, J. A., Lewandowski, G. S., et al. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0286 · Cited by 48
Self-citationMoore, D. H., Blessing, J. A., Dunton, C. J., Buller, R. E., & Reid, G. C. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5652 · Cited by 33
Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer
Slomovitz, B. M., Chelariu-Raicu, A., Schmeler, K. M., Lu, K. H., Gershenson, D. M., Wolf, J. K., & Coleman, R. L. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001859 · Cited by 15
Cited by
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Cohn, D., Crispens, M. A., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0006 · Cited by 643
Current recommendations and recent progress in endometrial cancer
Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21561 · Cited by 573
Metadata
- Authors
- Aghajanian, C., Sill, M. W., Darcy, K. M., Greer, B., McMeekin, D. S., Rose, P. G., Rotmensch, J., Barnes, M. N., Hanjani, P., & Leslie, K. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-01
- Volume
- 29
- Issue
- 16
- Pages
- 2259-2265
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154516141
- Cited by
- 326
- References
- 31
- FWCI
- 29.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.